{"id":"mdi-multiple-dose-insulin-injection","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Multiple dose insulin injection therapy involves administering insulin subcutaneously multiple times per day (typically 3-4 injections) to mimic physiological insulin secretion patterns. This regimen combines basal insulin (long-acting) with bolus insulin (rapid-acting) at mealtimes to achieve glycemic control by facilitating glucose uptake into cells and suppressing hepatic glucose production.","oneSentence":"MDI delivers insulin via multiple daily injections to replace or supplement endogenous insulin production and regulate blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:54:06.767Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when oral agents or other therapies are insufficient)"}]},"trialDetails":[{"nctId":"NCT06236607","phase":"NA","title":"Hybrid Closed Loop Effectiveness Trial in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Boston Medical Center","startDate":"2025-02-27","conditions":"Diabetes Mellitus, Type 1, Diabetes Complications","enrollment":140},{"nctId":"NCT06411548","phase":"NA","title":"InsuLearn Feasibility With Type 1 Diabetes Patients Under MDI Therapy","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2025-03-27","conditions":"Type 1 Diabetes Mellitus","enrollment":7},{"nctId":"NCT06529705","phase":"NA","title":"Performance and Safety Evaluation of the EkiYou V2 Application in Patients With Diabetes Using Multiple Daily Insulin Injections (EkiYou-Study1)","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2024-08-19","conditions":"Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes","enrollment":21},{"nctId":"NCT04538352","phase":"PHASE4","title":"Transition From Basal/Bolus to Once-weekly Subcutaneous Semaglutide and Basal Insulin in Patients With T2D","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2021-01-18","conditions":"Type 2 Diabetes","enrollment":60},{"nctId":"NCT05923827","phase":"NA","title":"Omnipod® 5 With Libre 2 vs. MDI for Type 1 Diabetes in Children and Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insulet Corporation","startDate":"2023-09-11","conditions":"Diabetes Mellitus, Type 1","enrollment":200},{"nctId":"NCT04123054","phase":"NA","title":"A Novel mHealth Application Guided by an Optimization Algorithm for T1D Sensor-Augmented Insulin Injection Users","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-03-05","conditions":"Diabetes Mellitus, Diabetes Mellitus, Type 1","enrollment":84},{"nctId":"NCT05029271","phase":"NA","title":"InPen User Experience","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2023-04-17","conditions":"Diabetes Type 1","enrollment":34},{"nctId":"NCT04938557","phase":"NA","title":"Automated Insulin Delivery Amongst Pregnant Women With Type 1 Diabetes","status":"COMPLETED","sponsor":"Norfolk and Norwich University Hospitals NHS Foundation Trust","startDate":"2019-09-26","conditions":"Diabetes","enrollment":124},{"nctId":"NCT05574023","phase":"NA","title":"Effect of CGM With Predictive Alarm on Hypoglycemia in Young Patients With T1D.","status":"COMPLETED","sponsor":"Azienda Ospedaliera Universitaria Integrata Verona","startDate":"2021-05-10","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT03557892","phase":"NA","title":"Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes","status":"COMPLETED","sponsor":"Azienda Ospedaliero-Universitaria Careggi","startDate":"2018-04-01","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT04945070","phase":"PHASE4","title":"INSULIN THERAPY DE-INTENSIFICATION WITH iGlarLixi","status":"UNKNOWN","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2021-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":96},{"nctId":"NCT01616784","phase":"PHASE3","title":"The REPOSE (Relative Effectiveness of Pumps Over MDI and Structured Education) Trial","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2011-11","conditions":"Type 1 Diabetes","enrollment":267},{"nctId":"NCT04014569","phase":"NA","title":"Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational & Proof of Concept Study","status":"TERMINATED","sponsor":"Rabin Medical Center","startDate":"2018-05-02","conditions":"Type 1 Diabetes, Multiple Daily Injections","enrollment":6},{"nctId":"NCT03793283","phase":"","title":"Continuous Subcutaneous Insulin Infusion Versus Multiple Dose Insulin Injections in Routine Clinical Practice","status":"COMPLETED","sponsor":"Castilla-La Mancha Health Service","startDate":"2019-01-01","conditions":"Type 1 Diabetes Mellitus","enrollment":90},{"nctId":"NCT03764280","phase":"NA","title":"The Efficacy of MDI Treatment With an Optimization Algorithm Adjusting Basal-Bolus Parameters in Children and Adolescents With Type 1 Diabetes at a Diabetes Camp","status":"COMPLETED","sponsor":"McGill University","startDate":"2018-07-02","conditions":"Diabete Mellitus, Diabetes Mellitus, Type 1","enrollment":21},{"nctId":"NCT01941238","phase":"","title":"Incidence of Hypoglycemia During Ramadan in Patients With Type1 Diabetes on Insulin Pump Versus Multi Dose Injection","status":"COMPLETED","sponsor":"Reem Mohammad Alamoudi","startDate":"2013-07","conditions":"Type 1 Diabetes","enrollment":142},{"nctId":"NCT02113332","phase":"PHASE2","title":"Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT01460446","phase":"NA","title":"ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-10","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":218},{"nctId":"NCT00942318","phase":"PHASE4","title":"Efficacy of Continuous Subcutaneous Insulin Infusion Versus Basal-bolus Multiple Daily Injections Regimen in Type 2 Diabetes","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2009-03","conditions":"Type 2 Diabetes Mellitus","enrollment":52},{"nctId":"NCT01574508","phase":"PHASE4","title":"Continuous Subcutaneous Insulin Infusion strAtegy Versus Multiple Daily Insulin Injections strAtegy","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2011-12","conditions":"Type 2 Diabetes","enrollment":120},{"nctId":"NCT00211536","phase":"PHASE3","title":"Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2002-06","conditions":"Type 1 Diabetes","enrollment":107},{"nctId":"NCT00530023","phase":"PHASE4","title":"Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness","status":"COMPLETED","sponsor":"Medtronic Diabetes","startDate":"2006-02","conditions":"Type 1 Diabetes","enrollment":29},{"nctId":"NCT00147836","phase":"NA","title":"Evaluation of the Effects of Different Interventions on Glycemic Control in Newly-Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2004-09","conditions":"Type 2 Diabetes Mellitus","enrollment":436}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MDI - Multiple dose insulin injection","genericName":"MDI - Multiple dose insulin injection","companyName":"Institute for Clinical and Experimental Medicine","companyId":"institute-for-clinical-and-experimental-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MDI delivers insulin via multiple daily injections to replace or supplement endogenous insulin production and regulate blood glucose levels. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus (when oral agents or other therapies are insufficient).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}